In its inherent mode of action as an MRA, finerenone may elevate serum potassium concentrations, particularly in patients with advanced CKD receiving the maximum tolerated dose of an inhibitor of the renin‐angiotensin system (RAS). This evidence concerns the gene REN and chronic kidney disease.